Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORCA risperidone discontinuation trial in children and adolescents
NL-OMON44901Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in Disruptive behavior disorders (DBD), Aggression (not a disease; see rationale) and irritability comparing Continued risperidone with Gradual discontinuation to placebo (2 arms). Primary endpoint: Nisonger Child Behavior Rating Form-Typical IQ (NCBRF-TIQ) D-total score. Started Jan 2016; status: recruiting.
02
Drugs
risperidone
03
Conditions
Disruptive behavior disorders (DBD)Aggression (not a disease; see rationale)irritability
Beyond the preview
Go deeper on NL-OMON44901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44901.